Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Validation of xMAP SARS-CoV-2 Multi-Antigen IgG assay in Nigeria

Autor: Nnaemeka C. Iriemenam, Fehintola A. Ige, Stacie M. Greby, Augustine Mpamugo, Ado G. Abubakar, Ayuba B. Dawurung, Mudiaga K. Esiekpe, Andrew N. Thomas, Mary U. Okoli, Samuel S. Awala, Blessing N. Ugboaja, Chicago C. Achugbu, Ifeanyichukwu Odoh, Felicia D. Nwatu, Temitope Olaleye, Loveth Akayi, Oluwaseun O. Akinmulero, Joseph Dattijo, Edewede Onokevbagbe, Olumide Okunoye, Nwando Mba, Ndidi P. Agala, Mabel Uwandu, Maureen Aniedobe, Kristen A. Stafford, Alash’le Abimiku, Yohhei Hamada, Mahesh Swaminathan, McPaul I. Okoye, Laura C. Steinhardt, Rosemary Audu

Publikováno v: PloS one. 17(4)

Objective There is a need for reliable serological assays to determine accurate estimates of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence. Most single target antigen assays have shown some limitations in Africa. To asse

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cfe7900482851c1d59b48d8885c2039c
https://pubmed.ncbi.nlm.nih.gov/35363818

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

SARS-CoV-2 Serologic Surveillance Among People Living with HIV in Nigeria, April 2022-January 2023.

Autor: Chun HM; Division of Global HIV & Tuberculosis, Global Health Center, US Centers for Disease Control and Prevention, Atlanta, Georgia, USA. Electronic address: vgi2@cdc.gov., Osawe S; Institute of Human Virology, Abuja, FCT, Nigeria., Adams-Dabban S; Institute of Human Virology, Abuja, FCT, Nigeria., Favaloro J; Division of Global HIV & Tuberculosis, Global Health Center, US Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Iriemenam NC; Division of Global HIV & Tuberculosis, Global Health Center, US Centers for Disease Control and Prevention, Abuja, FCT, Nigeria., Dirlikov E; Division of Global HIV & Tuberculosis, Global Health Center, US Centers for Disease Control and Prevention Mozambique, Maputo, Mozambique., Martin D; Division of Parasitic Diseases and Malaria, National Center for Emerging and Zoonotic Infectious Diseases, US Centers for Disease Control and Prevention, Atlanta, Georgia., Milligan K; Division of Global HIV & Tuberculosis, Global Health Center, US Centers for Disease Control and Prevention, Atlanta, Georgia, USA; Peraton Inc., Herndon, VA, USA., Abutu A; Division of Global HIV & Tuberculosis, Global Health Center, US Centers for Disease Control and Prevention, Abuja, FCT, Nigeria., Okunoye O; Division of Global HIV & Tuberculosis, Global Health Center, US Centers for Disease Control and Prevention, Abuja, FCT, Nigeria., Okoli M; Nigeria Centre for Disease Control and Prevention, Abuja, FCT, Nigeria., Akanbi O; Nigeria Centre for Disease Control and Prevention, Abuja, FCT, Nigeria., Akinmulero O; Institute of Human Virology, Abuja, FCT, Nigeria., Okonkwo R; Institute of Human Virology, Abuja, FCT, Nigeria., Oyedele O; Institute of Human Virology, Abuja, FCT, Nigeria., Greby S; Division of Global HIV & Tuberculosis, Global Health Center, US Centers for Disease Control and Prevention, Abuja, FCT, Nigeria., Abimiku A; Institute of Human Virology, Abuja, FCT, Nigeria., Okoye MIJ; Division of Global HIV & Tuberculosis, Global Health Center, US Centers for Disease Control and Prevention, Abuja, FCT, Nigeria., Shiraishi RW; Division of Global HIV & Tuberculosis, Global Health Center, US Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Adegoke D; Division of Global HIV & Tuberculosis, Global Health Center, US Centers for Disease Control and Prevention, Abuja, FCT, Nigeria., Bello M; Division of Global HIV & Tuberculosis, Global Health Center, US Centers for Disease Control and Prevention, Abuja, FCT, Nigeria., Villeng F; Nigeria Centre for Disease Control and Prevention, Abuja, FCT, Nigeria., Item II; Nigeria Centre for Disease Control and Prevention, Abuja, FCT, Nigeria., Gabo S; Nigeria Centre for Disease Control and Prevention, Abuja, FCT, Nigeria., Abubakar A; Institute of Human Virology, Abuja, FCT, Nigeria., Thomas A; Institute of Human Virology, Abuja, FCT, Nigeria., Olaleye T; Institute of Human Virology, Abuja, FCT, Nigeria., Awala S; Institute of Human Virology, Abuja, FCT, Nigeria., Nwatu F; Institute of Human Virology, Abuja, FCT, Nigeria., Ugboaja B; Institute of Human Virology, Abuja, FCT, Nigeria., Udoh I; Institute of Human Virology, Abuja, FCT, Nigeria., Akayi L; Institute of Human Virology, Abuja, FCT, Nigeria., Dattijo J; Institute of Human Virology, Abuja, FCT, Nigeria., Adenekan T; Institute of Human Virology, Abuja, FCT, Nigeria., Aminu-Alhaji A; Division of Global Health Protection, US Centers for Disease Control and Prevention Abuja, FCT, Nigeria., Ezeuko I; Division of Global HIV & Tuberculosis, Global Health Center, US Centers for Disease Control and Prevention, Abuja, FCT, Nigeria.

Publikováno v: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases [Int J Infect Dis] 2024 Nov 21, pp. 107309. Date of Electronic Publication: 2024 Nov 21.